v3.26.1
Warrants - Schedule of Key Inputs into Monte Carlo Simulation (Details)
Mar. 31, 2026
Dec. 31, 2025
Dec. 31, 2024
Class of Warrant or Right [Line Items]      
Warrants and rights outstanding, term (year) 6 months 21 days 9 months 21 days  
Measurement Input, Risk Free Interest Rate [Member]      
Class of Warrant or Right [Line Items]      
Warrants, outstanding inputs 0.0375 0.0383  
Measurement Input, Option Volatility [Member]      
Class of Warrant or Right [Line Items]      
Warrants, outstanding inputs 2.317 2.004  
Measurement Input, Share Price [Member]      
Class of Warrant or Right [Line Items]      
Warrants, outstanding inputs 0.0383 0.0374  
Preferred Tranche B Warrants [Member]      
Class of Warrant or Right [Line Items]      
Warrants and rights outstanding, term (year)     2 months 23 days
Preferred Tranche B Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]      
Class of Warrant or Right [Line Items]      
Warrants, outstanding inputs     0.0393
Preferred Tranche B Warrants [Member] | Measurement Input, Option Volatility [Member]      
Class of Warrant or Right [Line Items]      
Warrants, outstanding inputs     0.75
Preferred Tranche C Warrants [Member]      
Class of Warrant or Right [Line Items]      
Warrants and rights outstanding, term (year) [1] 2 years 7 months 28 days 2 years 10 months 28 days  
Preferred Tranche C Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]      
Class of Warrant or Right [Line Items]      
Warrants, outstanding inputs [1] 0.038 0.0354  
Preferred Tranche C Warrants [Member] | Measurement Input, Option Volatility [Member]      
Class of Warrant or Right [Line Items]      
Warrants, outstanding inputs 1.025 1.05  
Preferred Tranche C Warrants [Member] | Preferred Series A [Member] | Measurement Input, Share Price [Member]      
Class of Warrant or Right [Line Items]      
Warrants, outstanding inputs 3.1229 3.0495  
[1] Reflects a probability-weighted input derived from multiple Black-Scholes calculations. These calculations incorporate the Company’s estimated probability of dissolution, should SABS’ intellectual property fail to yield positive results in forthcoming clinical trials, potentially leading to dissolution before 2028. The probability was 47.5% as of March 31, 2026 and December 31, 2025.